Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q4 FY25 results · Jan–Mar 2025
Supriya Lifescience reported revenue from operations of ₹184.11 crore (up 16.4% from Q4 FY24) and net profit of ₹50.38 crore (up 36.4% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a standalone basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 184.11 | 158.18 | +16.4% | 185.65 | −0.8% |
| Other income | 2.98 | 2.19 | +36.2% | 2.10 | +41.8% |
| Total income | 187.08 | 160.37 | +16.7% | 187.75 | −0.4% |
| Profit before tax | 64.06 | 53.17 | +20.5% | 62.58 | +2.4% |
| Net profit for the period | 50.38 | 36.93 | +36.4% | 46.78 | +7.7% |
| EPS, basic (₹) | 6.29 | 4.59 | +37.0% | 5.82 | +8.1% |
| Net margin (%) | 27.4 | 23.3 | 25.2 |
Standalone
- Filed with BSE
- 27 May 2025, 18:28 IST
- Board meeting
- 27 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE